Hans Edgar Bishop - 08 Sep 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Director
Signature: /s/ Charles Newton, as Attorney-in-Fact
Issuer symbol: LYEL
Transactions as of: 08 Sep 2022
Net transactions value: +$14,538
Form type: 4
Filing time: 09 Sep 2022, 16:05:52 UTC
Previous filing: 07 Jul 2022
Next filing: 06 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Options Exercise	$14,538	+145,380	+3.2%	$0.1000^*	4,685,614	08 Sep 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Options Exercise	$0	-145,380	-86%	$0.000000	24,230	08 Sep 2022	Common Stock	145,380	$0.1000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.